Irritable bowel syndrome (IBS) is one of the most common and best studied disorders among the group of functional gastrointestinal disorders. It is a functional bowel disorder in which abdominal pain or discomfort is associated with defecation or a change in bowel habit. Visceral hypersensitivity and increased GIT motility are the main patho-physiological mechanism for developing IBS. IBS present with diarrhoea or constipation or both. 
Introduction
Irritable bowel syndrome (IBS) has been recognized as one of the most common and best studied disorder among the group of functional gastrointestinal disorders 1 . It is a functional bowel disorder in which abdominal pain or discomfort is associated with defecation or a change in bowel habit 2 . Prevalence of IBS in adults is gradually increasing, about 20% in western population 3 , 6.5-10.1% in Asian countries 4 and 4% in northern India, showing in recent studies 5 . One study of children in North America found that 14% of high school students and 6% of middle school students have IBS. The study also found that IBS affects boys and girls equally 6 . Through its exact incidence is hard to assess, but it appears that those attending gastroenterology clinics represent a few person go to the tertiary centre from where the above prevalence data are collected 7 . Some questions therefore remain to be answered -Is there a significant difference in the incidence of IBS in developing and developed countries? Will the incidence of IBS increase by adoption of a Western lifestyle? Are predisposing factors different in developing and developed countries? Is the increasing stress on young children to achieve or family break-up responsible for IBS symptoms becoming evident at a younger age? The answer is probably 'yes' to a certain extent. Infective pathology is considered the trigger for IBS in developing country. According to Rome III criteria1, for the diagnosis of IBS following requirements are needed-Criteria must include both of the following: 1. Abdominal discomfort or pain associated with two or more of the following at least 25% of the time: a) Improvement with defecation; b) Onset associated with a change in frequency of stool and c) Onset associated with a change in form (appearance) of stool 2. No evidence of an inflammatory, anatomic, metabolic, or neoplastic process that explains the subject's symptoms. Criteria fulfilled at least once per week for at least 2 months prior to diagnosis. Discomfort means an uncomfortable sensation not described as pain. • Mal-absorption: The development of idiopathic bile acid mal-absorption has been observed following enteric infections, which may be result in diarrhea-predominant IBS.
• Increase in entero-endocrine cells/lymphocytes: An increase in serotonin-containing entero-endocrine cells and T lymphocytes, has been demonstrated following acute Campylobacter enteritis.
• Antibiotic use: The use of antibiotics for GI or other infections may be a risk factor for developing functional bowel symptoms.
• Bacterial overgrowth-Small intestinal bacterial overgrowth may be associated with IBS 15 .
Alteration in Fecal Microflora
Changes in the composition of intestinal microflora may be associated with IBS. Patients with diarrhea-predominant IBS would benefit from probiotics, which influence the composition and metabolism of the microflora 16 
.5. Fiber
A decrease in fiber intake to 12 g per day (particularly insoluble fiber such as bran) was suggested in a British guideline, because of the potential of fiber to exacerbate symptoms. An increase in the intake of fiber is often recommended. Proposed mechanisms for fiber's beneficial effects include: enhancement of water holding properties of the stool; formation of gels to provide lubrication; bulking of the stool; and binding of agents such as bile. Clinical trials found no convincing evidence that the commonly-used bulking agents were more effective than placebo at relieving global IBS symptoms. Although the efficacy of fiber supplements has not been proven 23 , some improvement has been demonstrated in patients with IBS whose primary complaints are abdominal pain and constipation. Dose of fibre is age plus 5 grams of fiber daily. 6.3. Medication Pharmacologic agents are only an adjunct to treatment in irritable bowel syndrome (IBS). Furthermore, the drug chosen varies depending on the patient's major symptoms; diarrhea-predominant IBS is treated differently from constipation-predominant disease. 6.3.1. Antispasmodic agents: The antispasmodic agents include 6.3.1.1. Directly affect intestinal smooth muscle relaxation eg, mebeverine, pinaverine, pepperment oil. Mebeverine is licensed in the United Kingdom and is generally well tolerated; and can be used on an as required basis before meals. A systematic review which searched medical databases and all relevant literature from 1965 to June 2009 for any placebo-controlled clinical trials of mebeverine, identified 14 relevant papers (8 were randomized trials with 555 patients) and concluded that mebeverine is mostly well tolerated with no significant adverse effects; however, its efficacy in global improvement of IBS was not found to be statistically significant 24 . 6.3.1.2. Act via their anticholinergic or antimuscarinic properties like Dicyclomine and hyoscyamine, duration on demand basis; Inhibition of GI smooth muscle reduces stimulated colonic motor activity & may be beneficial in patient with postprandial abdominal pain, gas, bloating, and fecal urgency. 6.3.2. Antidepressants Antidepressants have analgesic properties independent of their mood improving effects and may therefore be beneficial in patients with neuropathic pain. The postulated mechanisms of pain modulation with tricyclic antidepressants( TCA) and possibly serotonin reuptake inhibitors in IBS are facilitation of endogenous endorphin release, blockade of norepinephrine reuptake leading to enhancement of descending inhibitory pain pathways, and blockade of the pain neuro-modulator, serotonin. TCAs, via their anti-cholinergic properties, also slow intestinal transit time, which provide benefit in diarrhea-predominant IBS. Improvement in neuropathic pain with TCAs occurs at lower doses than required for treatment of depression. As a result, if an antidepressant is chosen for the treatment of IBS, low doses should be administered initially and titrated to pain control or tolerance. Because of the delayed onset of action, three to four weeks of therapy should be attempted before considering treatment insufficient and increasing the dose. Examples of antidepressant medications used in patients with IBS include amitriptyline, imipramine, nortriptyline, and desipramine. The initial dose should be adjusted based upon tolerance and response. TCAs should be used cautiously in patients with constipation. Amitriptyline, nortriptyline, and imipramine can be started at a dose of 10 to 25 mg at bedtime and increased every three to four weeks based upon clinical response and tolerance 25 . Desipramine is used in a similar fashion beginning at 12.5 to 25 mg at bedtime. If the patient is intolerant of one TCA, another may be tried. Paroxetine (10 to 20 mg daily), fluoxetine (20 to 40 mg daily), sertraline (50 to 100 mg daily), or other antidepressant medications can be considered if depression is a cofactor. 6.3.3. Benzodiazepines Anxiolytic agents are of limited usefulness in IBS because of the risk of drug interactions, habituation, and rebound withdrawal. Furthermore, benzodiazepines may lower pain thresholds by stimulating gamma aminobutyric acid (GABA) receptors, thereby decreasing brain serotonin. They may, however, be useful for short-term (less than two weeks) reduction of acute situational anxiety that may be contributing to symptoms. 6.3.4. 5-hydroxytryptamine 3 receptor antagonists 5-hydroxytryptamine-3 receptor antagonists such as ondansetron, alosetron and graniosetron modulate visceral afferent activity from the gastrointestinal tract and may improve abdominal pain. 6.3.5. 5-hydroxytryptamine 4 receptor agonists Agonists of 5-hydroxytryptamine-4 receptor stimulate the release of neurotransmitters and increase colonic motility, providing a rationale for their use in constipation predominant IBS. The first of this class of drugs is tegaserod was approved for IBS and constipation but removed from the market due to cardiovascular side-effects. 6.3.6. Lubiprostone Lubiprostone is a locally acting chloride channel activator that enhances chloride-rich intestinal fluid secretion. Lubiprostone has been approved by the United States Food and Drug Administration for treatment of irritable bowel syndrome with constipation in women 18 years and older. The approved dose is 8 micrograms twice daily for 12 weeks 26 . 6.3.7. Linaclotide An agonist of guanylatecyclase, linaclotide is a unique agent which was recently approved by both American and European regulatory agencies for the treatment of IBS-C. Stimulation of guanylatecyclase receptors leads to increased secretion of both guanylin and uroguanylininto the intestinal lumen where they act as a second messenger for both fluid and electrolyte release into the large bowel 27 . Linaclotide is minimally absorbed and has a strong affinity for the guanylatecyclase receptor. 6.3.8. Other Drugs Pepperment oil, laxatives-polyethylene glycol, mast cell stabilizer, antibiotics-rifaximin, probiotics, loperamide 6.3.8.1. Mast cell stabilizers Ketotifen is a mast cell stabilizer that has been studied for the treatment of IBS based upon the theory that mast cell activation contributes to visceral hypersensitivity. In a randomized trial of 60 patients, the use of ketotifen for eight weeks increased the threshold for discomfort with rectal distension in patients who were hypersensitive to rectal balloon distension at baseline, but not in those with normal sensitivity at baseline. in patients who received ketotifen compared with those who received placebo, the results did not reach statistical significance. 6.3.8.2. Antibiotics Rifaximin, a nonabsorbable antibiotic, led to symptomatic improvement in global IBS symptoms and bloating. The mechanisms leading to the benefit are unclear but may be due to suppression of gas producing bacteria in the colon. It is reasonable to consider two-week trial of rifaximin 28 . 6.4. Physical Activity and Psychosocial Therapy 6.4.1. Physical activity Increased physical activity may help with the symptoms of IBS. Increased physical activity was comprised of 20 to 60 minutes of moderate to vigorous activity three to five days per week. 6.4.2. Psychosocial therapies Behavioral treatments may be considered for motivated patients who associate symptoms with stressors, although their benefits remain controversial. Hypnosis, biofeedback, and psychotherapy help to reduce anxiety levels, encourage health promoting behavior, increase patient responsibility and involvement in the treatment, and improve pain tolerance.
Conclusion
IBS is a clinical diagnosis of exclusion. The diagnosis is challenging because of the nature and range of associated symptoms and their interpretation amongst parents and pediatricians. A detailed focused history and use of Rome III criteria will be helpful to clarify uncertainties about the diagnosis. Investigations should be kept to the minimum and used for selected cases to exclude other serious pathologies with similar presenting features. For successful management of IBS in children initially enough time should be spent at explaining and reassuring the child and the parents. Therapy needs to be individualized to patient needs. Before initiating therapy it is important to explain the expected benefits and possible side-effects to the family. Multi-disciplinary team approach is needed for management of difficult cases.
